ASSOCIATION OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL WITH INCIDENT CARDIOVASCULAR EVENTS IN WOMEN, BY LOW-DENSITY LIPOPROTEIN CHOLESTEROL AND APOLIPOPROTEIN.

Slides:



Advertisements
Similar presentations
Summary Prepared by Melvyn Rubenfire, MD
Advertisements

Robert M. Guthrie, MD Professor of Emergency Medicine
YOUR CHOLESTEROL WHY DO YOU CARE? WHAT YOU CAN DO !
© Copyright 2009 by the American Association for Clinical Chemistry LOX Index, a Novel Predictive Biochemical Marker for Coronary Heart Disease and Stroke.
Break the Fast: “Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control.
New concepts and guidelines in the management of LDL-c and CV Risk: Need for early intervention Prof. Ulf Landmesser University Hospital Zürich Switzerland.
Clinical Trial Results. org Based on the Iron (Fe) and Atherosclerosis Study (FeAST) Leo R. Zacharski, MD; Bruce K. Chow, MS; Paula S. Howes, MS, APRN;
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
Cholesterol. The Good the Bad the Ugly.
Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?
Ross Bryan Medical Student MS III Mercer University August 2012 Effect of Supplementation With High-Selenium Yeast on Plasma Lipids Annals of Internal.
Clinical Trial Results. org Value of Lipoprotein Particle Number and Size as Predictors of Coronary Artery Disease in Apparently Healthy Men and Women:
Clinical Trial Results. org Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis Stephen J. Nicholls, MBBS, PhD; E.
{ A Novel Tool for Cardiovascular Risk Screening in the Ambulatory Setting Guideline-Based CPRS Dialog Adam Simons MD.
THE LIPID PANEL What are we missing? Robert St. Amant, MD, FAAFP Diplomate, American Board of Clinical Lipidology Baton Rouge General Medical Director,
Global impact of ischemic heart disease World Heart Federation, 2011.
Lipoproteins Clusters of lipids associated with proteins that serve as transport vehicles for lipids in the lymph and blood.
Madhav Vissa. ATP III  Adult Treatment Panel  Guidelines for tx of High Cholesterol  Based on epidemiological evidence about risk factors for CHD.
By: David Tran, Mercer University, 2013 Pharm.D. Candidate Prececptor: Dr. Ali Rahimi Morbidity and Mortality Associated with Dyslipidemia.
Fenofibrate Intervention and Event Lowering in Diabetes FIELDFIELD Presented at The American Heart Association Scientific Sessions, November 2005 Presented.
10 Points to Remember on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in AdultsTreatment of Blood Cholesterol to Reduce.
10 Points to Remember on the Assessment of Cardiovascular RiskAssessment of Cardiovascular Risk Summary Prepared by Melvyn Rubenfire, MD.
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.
Glynn RJ, et al. N Engl J Med 2009 Mar 29 [Epub ahead of print]
Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.
Incremental Decrease in Clinical Endpoints Through Aggressive Lipid Lowering (IDEAL) Trial IDEAL Trial Presented at The American Heart Association Scientific.
Cholesterol. What is cholesterol? Waxy, fat-like substance found in all cells. Dietary cholesterol – found only in animal-based foods Blood cholesterol.
Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 2 ARBITER-2 Trial Presented at The American Heart Association Scientific.
AA-2-1 Jerome D. Cohen, MD, FACC, FACP Professor of Internal Medicine / Cardiology Director, Preventive Cardiology Programs St. Louis University Health.
Clinical Trial Results. org SAGE Trial Prakash Deedwania, MD; Peter H. Stone, MD; C. Noel Bairey Merz, MD; Juan Cosin-Aguilar, MD; Nevres Koylan, MD; Don.
BRIAN CLAYTON INTERNAL MEDICINE ADVISOR: ANNA MAE SMITH PRECEPTOR: DR. RAJESH PATEL Evidence Based Medicine Spring 2009.
Bangalore S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13): ?
ACC/AHA Guidelines Not the Final or Only Word. Contemporary Guidelines
An aortic aneurysm can rupture (dissecting aneurysm) and cause massive blood loss, circulatory shock and rapid death.
Short Sleep Duration as a Predictor of Cardiovascular Events Summary and Comment by Jamaluddin Moloo, MD, MPH Published in Journal Watch General Medicine.
The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
Baseline characteristics of HPS participants by prior cerebrovascular disease.
Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial Michael Miller MD,
REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease Louise Bowman on behalf of the HPS.
The American Heart Association Presented by Dr. Steven E. Nissen
Triglycerides Cholesterol HDL-C or N NIDDM N or or N IDDM.
Atherosclerosis, Plaque Imaging
AIM HIGH Niacin plus Statin to prevent vascular events
HDL cholesterol and cardiovascular risk Epidemiological evidence
First time a CETP inhibitor shows reduction of serious CV events
Copyright © 2012 American Medical Association. All rights reserved.
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
HDL cholesterol and cardiovascular risk
AIM-HIGH Niacin Plus Statin to Prevent Vascular Events
Oxford Niacin Trial.
FATS- Familial Atherosclerosis Treatment Study
Neil J. Stone et al. JACC 2014;63:
Baseline characteristics of HPS participants by prior diabetes
The Hypertension in the Very Elderly Trial (HYVET)
Type 2 diabetes: Overlap of clinical conditions
Jonathan C. Cohen, PhD  Journal of Clinical Lipidology 
To B or Not to B: Is Non–High-Density Lipoprotein Cholesterol an Adequate Surrogate for Apolipoprotein B?  Carl J. Lavie, MD, Richard V. Milani, MD, James.
These slides highlight a presentation from a Special Session of the Late-Breaking Clinical Trials sessions during the American College of Cardiology 2005.
Potential mechanisms whereby statins may reduce the risk of stroke
Stephen J. Nicholls, MBBS, PhD; E
Baseline Characteristics of the Subjects*
LDL - How low can you go? Terry Jacobsen, MD
The Heart Rhythm Society Meeting Presented by Dr. Johan De Sutter
Opening a New Lipid “Apo-thecary”: Incorporating Apolipoproteins as Potential Risk Factors and Treatment Targets to Reduce Cardiovascular Risk  Terry.
Characteristics of included studies
The following slides highlight a report on a presentation at the American College of Cardiology 2004, Scientific Sessions, in New Orleans, Louisiana on.
Intensive Lowering of Low-Density Lipoprotein Cholesterol Levels for Primary Prevention of Coronary Artery Disease  Dean G. Karalis, MD  Mayo Clinic Proceedings 
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
Special Considerations for Different Population Groups
Presentation transcript:

ASSOCIATION OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL WITH INCIDENT CARDIOVASCULAR EVENTS IN WOMEN, BY LOW-DENSITY LIPOPROTEIN CHOLESTEROL AND APOLIPOPROTEIN B100 LEVELS ANNALS OF INTERNAL MEDICINE DECEMBER 2011 Gail Wiley D.O. Candidate GA-PCOM July 2012

Funding  Merck and Co., National Heart, Lung and Blood Institute, National Cancer Institute, National Institutes of Health

Background/ Objective:  studies have shown that high levels of HDL have a anti-atherogenic effect and LDL and has an atherogenic effect  HDL particles are able to remove cholesterol from within atheromas and transport it back to the liver for excretion or re-utilization  Does HDL still have this cardioprotective effect in women at all levels of LDL and apolipoprotein B100?  apo B100 is value measuring all LDL’s (inlcluding VLDLS and intermediate density LDL’s), which are also atherogenic  study focuses particulary on women  -answers questions not answered by the Framingham study

Why is this important?  CAD remains the number one cause of death in american women  LDL has been a target of therapy for prevention of CAD (statins), HDL receiving more attention and it is still unclear wether it should be a clinical focus for treatment  "Although clinical trial results suggest that raising HDL will reduce risk, the evidence is insufficient to specify a goal of therapy. Furthermore, currently available drugs do not robustly raise HDL cholesterol.“ -quote from Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults  HDL currently used to determine CAD risk (ie Framingham tables) but low values are not routinely treated

Study Design and Setting:  prospective cohort study  participants were apparently healthy female health care professionals, age 45 or older  27,000 women were followed for a mean of 11 years  baseline lipid measurements were done at the start of study

Endpoints included in analysis:  myocardial infarction  stroke  percutaneous coronary intervention  coronary artery bypass grafting  death from cardiovascular causes

Exclusions:  women with self-reported CAD or cancer  women on lipid lowering medications

Results:

cont.

Conclusion: This study confirms the inverse relationship between HDL cholesterol and adverse cardiovascular events in women.  HDL is cardioprotective in women with all levels of LDL- high or low  HDL is cardioprotective in women with moderate to increased apo-B (measure of all “bad fats”)  study could not determine wether HDL was cardioprotective in women with very low levels apoB- very few events occured  protective effect of HDL plateaus at a level of 67 mg/dL  HDL levels have little value in predicting stroke

Limitations:  study population was healthy women- unable to predict wether HDL is protective in women with pre- existing CAD  only one baseline lipid measurement was obtained

Comments: This study did a good job of highlighting the interaction between “good” and “bad” fats, demonstrating why the LDL to HDL ratio of better predictive value than LDL alone. Study also highlighted a need for there to be more research done on the relationship between cholesterol and stroke- only a weak correlation has been shown.

Sources:  Mora S et al. Association of high-density lipoprotein cholesterol with incident cardiovascular events in women, by low-density lipoprotein cholesterol and apolipoprotein B100 levels: A cohort study. Ann Intern Med 2011 Dec 6; 155:742.  Rafael Carmena, MD; Patrick Duriez, PhD; Jean-Charles Fruchart, PhD (2003, February 3 Atherosclerosis: Evolving Vascular Biology and Clinical Implications. Retrieved July 15, 2012, from  Vibhuti N Singh, MD, MPH, FACC, FSCAI. Low HDL Cholesterol (Hypoalphalipoproteinemia) Treatment & Management (2002). Retrieved July , from  Jamaluddin Moloo, MD, MPH (Jan 19,2012) Association of Lipid Subfractions and Cardiovascular Events in Women. Retrieved July 15,2012 from medicine.jwatch.org/cgi/content/full/2012/119/2